LOGIN
Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty
May 2013
Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
3148 patients who underwent total knee arthroplasty (TKA) were randomized to thromboprophylaxis using either orally administer rivaroxaban or subcutaneous injection of enoxaparin. This study assessed the efficacy of thromboprophylaxis treatment with rivaroxaban and assessed its non-inferiority to enoxaparin. The results of this study indicated that rivaroxaban was superior in comparison to enoxapa...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.